Royalty Pharma Reports Third Quarter 2025 Results
NEW YORK, NY, November 5, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.
News
Royalty Pharma Acquires Royalty Interest in Alnylam’s Amvuttra for $310 Million from Blackstone Life Sciences
NEW YORK, NY, and CAMBRIDGE, MA November 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million.
Royalty Pharma Declares Fourth Quarter 2025 Dividend
NEW YORK, NY, October 17, 2025 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share.
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
NEW YORK, NY, October 9, 2025 – Royalty Pharma plc today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open.
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
NEW YORK, NY, September 29, 2025 – Royalty Pharma plc today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.
Royalty Pharma To Present At Bernstein’s 2nd Annual Healthcare Forum
NEW YORK, NY, September 19, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
NEW YORK, NY, September 11, 2025 - Royalty Pharma plc will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to drive shareholder value creation through its unique business model and capabilities in the large and growing market for funding biopharma innovation with royalties.
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
NEW YORK, NY, September 10, 2025 – Royalty Pharma plc today announced the release of a biopharma royalty market study conducted by Deloitte.
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
NEW YORK, NY, September 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET.
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
NEW YORK, NY, September 2, 2025 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”)...
